U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07117760) titled 'Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer' on Aug. 05.

Brief Summary: PSMA is an ideal target for precision diagnosis and treatment of prostate cancer. LNC1011 is a novel albumin-binding PSMA-targeted radioligand. This study aims to explore the safety and efficacy of 225Ac-labeled LNC1011 for treating patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

Study Start Date: April 22

Study Type: INTERVENTIONAL

Condition: Prostate Cancer

Intervention: DRUG: 225Ac-LNC1011

administered intravenously once every 8-10 weeks (1 cycle) f...